Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trial.

ABSTRACT:

Background

Young children with sickle cell anaemia (SCA) often have slowed processing speed associated with reduced brain white matter integrity, low oxygen saturation, and sleep-disordered breathing (SDB), related in part to enlarged adenoids and tonsils. Common treatments for SDB include adenotonsillectomy and nocturnal continuous positive airway pressure (CPAP), but adenotonsillectomy is an invasive surgical procedure, and CPAP is rarely well-tolerated. Further, there is no current consensus on the ability of these treatments to improve cognitive function. Several double-blind, randomised controlled trials (RCTs) have demonstrated the efficacy of montelukast, a safe, well-tolerated anti-inflammatory agent, as a treatment for airway obstruction and reducing adenoid size for child

SUBMITTER: Hood AM 

PROVIDER: S-EPMC8502503 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature